Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Development of new thrombolytic substances]

U Zeymer1, K L Neuhaus

  • 1Städtische Kliniken Kassel, Medizinische Klinik II.

Herz
|December 1, 1994
PubMed
Summary

Early thrombolytic therapy improves survival in acute myocardial infarction but achieving artery patency remains challenging. Novel recombinant plasminogen activators show promise for more effective reperfusion and reduced mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the protocol: adherence to ECPR selection criteria and outcomes after Out-of-Hospital Cardiac Arrest (OHCA)-insights from the German Cardiac Arrest Registry (G-CAR).

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Community-based analysis of stroke prevention and effect of public interventions in atrial fibrillation: results from the ARENA project.

Clinical research in cardiology : official journal of the German Cardiac Society·2024
Same author

EU-CaRE study: Could exercise-based cardiac telerehabilitation also be cost-effective in elderly?

International journal of cardiology·2021
Same author

[Short version of the 2nd edition of the German-Austrian S3 guidelines "Cardiogenic shock complicating myocardial infarction-Diagnosis, monitoring and treatment"].

Der Anaesthesist·2020
Same author

Collateral damage of COVID-19-lockdown in Germany: decline of NSTE-ACS admissions.

Clinical research in cardiology : official journal of the German Cardiac Society·2020
Same author

[Dermatosurgery in the age of novel oral anticoagulants/direct oral anticoagulants].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2019

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Context:

  • Acute myocardial infarction (AMI) treatment relies on early reperfusion.
  • Thrombolytic therapy aims for rapid, sustained infarct-related artery (IRA) patency.
  • Current therapies achieve IRA patency in only ~50% of patients, impacting in-hospital mortality.

Purpose:

  • To review advancements in thrombolytic therapy for AMI.
  • To discuss recombinant plasminogen activators and 'designer drugs'.
  • To evaluate strategies for improving fibrinolytic efficacy and safety.

Summary:

  • Recombinant plasminogen activators (r-PAs), such as deletion mutants of tissue-plasminogen activator (t-PA), are under investigation.
  • A specific r-PA demonstrated high early patency rates in clinical trials, with one regimen showing superior efficacy compared to standard t-PA.
  • Chimeric activators and antibody complexes offer potential but face challenges like immunogenicity and cost.

Impact:

  • Improved thrombolytic strategies can significantly reduce mortality in AMI patients.
  • Development of more effective and safer fibrinolytic agents is crucial.
  • Recombinant production of plasminogen activators represents a promising therapeutic avenue.

Related Experiment Videos